<DOC>
	<DOCNO>NCT00621361</DOCNO>
	<brief_summary>This study ass safety tolerability Cediranib ( RECENTIN™ , AZD2171 ) combination etoposide cisplatin ( EP ) first line treatment lung cancer patient extensive stage metastatic disease EP would standard therapy .</brief_summary>
	<brief_title>Phase I Safety Tolerability Study Cediranib ( RECENTIN™ , AZD2171 ) Combination With Chemo First Line Lung Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Cancer diagnosis stage ( histological cytological confirm extensive stage lung cancer , EP would consider standard therapy , required time diagnosis . ) No prior chemotherapy immunotherapy advance stage lung cancer ( prior radiotherapy permit outside measurable field great equal 2 week prior entry study . ) WHO performance status 02 Untreated unstable brain meningeal metastases Patient inappropriate laboratory test value Inadequate bone marrow reserve .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Lung Cancer</keyword>
	<keyword>AZD2171</keyword>
	<keyword>cediranib</keyword>
	<keyword>RECENTIN</keyword>
	<keyword>etoposide</keyword>
	<keyword>cisplatin</keyword>
</DOC>